Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A new study has revealed that CSL Behring's C1-inhibitor concentrate is highly effective and safe in treating skin swelling in patients with hereditary angioedema.
Subscribe to our email newsletter
According to the study, relief of symptoms occurred in all treated attacks after 1.3 hours in the mean after receiving C1-inhibitor (C1-INH) concentrate. In all untreated attacks, the mean time to relief of symptoms was 60 hours.
Hereditary angioedema (HAE) is a genetic disorder caused by an inherited deficiency of C1-INH. Symptoms include episodes of edema or swelling in the hands and feet, the face, the abdomen and the larynx.
“Our findings show that replacement therapy with C1-INH concentrate can significantly reduce the duration and extent of symptoms in HAE patients who experience skin swelling during acute attacks of this serious disease,” said Dr Konrad Bork of the Department of Dermatology, Johannes Gutenberg University, Germany.
“This study adds to the growing body of research demonstrating the safety and efficacy of C1-INH concentrate in treating acute HAE attacks.”
CSL Behring is currently conducting C1-inhibitor trials, one of which is studying patients with acute abdominal or facial HAE attacks. The purpose of this phase II/III study is to demonstrate that human pasteurized C1-INH concentrate leads to faster relief of acute symptoms of abdominal and facial attacks compared to placebo.
No government-approved pharmaceutical product indicated specifically for treatment of acute HAE attacks, including abdominal attacks, is available in North America.